Vehicle

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease1
36Epidermolysis bullosa28
53Sjogren syndrome7
IDDisease name (Link within this page)Number of trials
160Congenital ichthyosis10
192Cockayne syndrome2

6. Parkinson disease


Clinical trials : 2,586Drugs : 1,871 - (DrugBank : 354) / Drug target genes : 188 - Drug target pathways : 205 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

36. Epidermolysis bullosa


Clinical trials : 183Drugs : 159 - (DrugBank : 51) / Drug target genes : 69 - Drug target pathways : 147 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

53. Sjogren syndrome


Clinical trials : 368Drugs : 277 - (DrugBank : 94) / Drug target genes : 62 - Drug target pathways : 186 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

160. Congenital ichthyosis


Clinical trials : 57Drugs : 68 - (DrugBank : 25) / Drug target genes : 21 - Drug target pathways : 141 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

192. Cockayne syndrome


Clinical trials : 4Drugs : 5 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathways : 49 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries